This model has been discontinued. Please see alternative model 23534 TKM30 NOG.

TK-NOG

Taconic Terms and Conditions
TK-NOG Mouse Model
Model No.NomenclatureGenotype
12907-FNOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-UL23)7-2/ShiJicsp/sp;ko/ko;tg/wt
12907-MNOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-UL23)7-2/ShiJicsp/sp;ko/y;tg/wt
View:
Select One

Overview

This model has been discontinued. Please see alternative model 23534 TKM30 NOG.


Nomenclature: NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-UL23)7-2/ShiJic

  • Also known as Alb-HSVtk-NOG and albumin-TK-NOG, super immunodeficient NOG mouse with transgenic expression of thymidine kinase under control of liver-restricted albumin promoter.
  • Useful for humanizing liver via engraftment with human hepatocytes and/or humanizing immune system via engraftment of human immune cells/tissues or hematopoietic stem cells.
  • Inducible ablation of murine hepatocytes by ganciclovir treatment enables stable, long-term engraftment of human hepatocytes.
  • The premiere model for human liver toxicity, metabolism, and infectious disease.
  • Other uses include safety and immunogenicity assessment.
  • Please note the scientific nomenclature of this strain was updated in Sept 2021 to reflect most current allele designations.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
 
What our customers say:

“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH

Recommended Controls
The recommended control for this model is CIEA NOG mouse.

Origin

The NOG mouse was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The NOG mouse was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The HSVtk transgene was generated by CIEA via microinjection into NOD/Shi inbred mice. The transgenic construct contains the mouse albumin enhancer/promoter (mAlb En/Pro), the chimeric intron, HSVtk cDNA, and the 3'-UTR of the human growth hormone gene with a polyadenylation signal (hGH pA). There was a single site of transgene integration, and HSVtk mRNA was selectively expressed in the liver. The TK-NOD/Shi mice were backcrossed onto the NOG mouse at CIEA and imported into Taconic in 2014.

Genetics

Species:Mouse
Strain Type:Congenic
Allele Type:Constitutive Knockout;Spontaneous Mutant;Random Transgenic
Coat Color:Albino
Genetic Background:NOD

Guides & Publications

Initial Publication: 

  • Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. (2011) Biochem Biophys Res Commun. 18;405(3):405-10.
  • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γγ mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
See all publications

Applications & Therapeutic Areas

  • ADMET
  • Cell and Tissue Humanized
  • Metabolic Disease
  • Infectious Disease

Transit, Housing & Welfare

Need more info? Click the live chat button or Contact Us

Packing Practices

Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns.  When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.

Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age."  Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.

Taconic discourages other types of custom packing requests as they can have a negative impact on animal welfare. Learn more.

Webinar On-Demand

ON-DEMAND PRESENTATION | Humanized Immune System (HIS) Mice: Breakthrough Models for Immuno-Oncology Drug Discovery

Watch Now

Request 2026 Pricing

Receive information on 2026 pricing from Taconic Biosciences today.

Request Pricing
Pricing Guide